PROCEDURES FOR THE GENETIC MODIFICATION OF HEMATOPOYETIC PROGENITING CELLS AND USES OF THE MODIFIED CELLS.

摘要

Composition for use in the treatment of HIV infection in a human subject, comprising a pharmaceutically acceptable carrier and at least 1.63 x 10 6 CD34 + hematopoietic cells per kg body weight of a human subject to which it should be administered the composition, being at least 0.52 X 10 6 of said CD34 + hematopoietic cells per kg body weight of said subject transduced with a viral construct expressing an anti-HIV agent and in which the transduced CD34 + cells can be grafted, giving rise to progeny cells for at least 12 months, in the subject.